Tekla Life Sciences Investors – NYSE:HQL

Add to watchlist

$13.99

+0.49

+3.63%

Market closed

Open in 4 minutes

-9.82%

month

-9.82%

quarter

-0.73%

year

Market Cap	368.41M
Enterprise value	369.23M

P/E	9.51
EV/Sales	11.67
EV/EBITDA	9.51
Price/Sales	11.67
Price/Book	0.80
PEG ratio	0.27
EPS	1.6

Revenue	60.85M
EBITDA	44.30M
Income	44.30M
Revenue Q/Q	N/A
Revenue Y/Y	N/A

Profit margin	122.69%
Oper. margin	-38.26%
Gross margin	91.81%
EBIT margin	-38.26%
EBITDA margin	72.81%

Get more financial ratios!

Every financial ratio you might need
10 years history
Forward ratios (Analysts estimates)

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Tekla Life Sciences Investors (NYSE:HQL): Profit margin
Sep 2022	21.69M	-28.30M	-130.5%
Mar 2023	9.82M	33.80M	344.19%
Sep 2023	29.56M	-11.45M	-38.73%
Mar 2024	-225.19K	50.25M	-22317.15%

Tekla Life Sciences Investors (NYSE:HQL): Debt to assets
Dec 2022	432689000	10.04M	2.32%
Mar 2023	432689116	10.04M	2.32%
Sep 2023	402600476	666.95K	0.17%
Mar 2024	441947451	879.91K	0.2%

Tekla Life Sciences Investors (NYSE:HQL): Cash Flow
Jun 2022	0	0	0
Sep 2022	0	0	0
Mar 2023	0	0	0
Sep 2023	0	0	0

Tekla Life Sciences Investors
Insider Trading

Tekla Life Sciences Investors (NYSE:HQL): Insider trades (number of shares)
Period	Buy	Sel
Sep 2023	22096	0
Dec 2023	1000	0
Jan 2024	1000	0
Apr 2024	429802	0
May 2024	278464	0
Jun 2024	109323	0
Jul 2024	1000	0
Aug 2024	650	0

Transaction	Date	Insider	Security	Shares	Price per share	Total value
Purchase	23 Aug 2024	MAHER BILL director director	Common Stock	650	$15.37	$9,991
Purchase	16 Jul 2024	DIMARTINO ROSE director director	Common Stock	1,000	$15.53	$15,530
Purchase	26 Jun 2024	SABA CAPITAL MANAGEMENT, L.P. 10 percent owner 10 percent owner	Common Stock	100	$14.07	$1,407
Purchase	24 Jun 2024	SABA CAPITAL MANAGEMENT, L.P. 10 percent owner 10 percent owner	Common Stock	13,812	$14.08	$194,473
Purchase	13 Jun 2024	SABA CAPITAL MANAGEMENT, L.P. 10 percent owner 10 percent owner	Common Stock	8,467	$13.82	$117,014
Purchase	12 Jun 2024	SABA CAPITAL MANAGEMENT, L.P. 10 percent owner 10 percent owner	Common Stock	2,400	$13.88	$33,312
Purchase	11 Jun 2024	SABA CAPITAL MANAGEMENT, L.P. 10 percent owner 10 percent owner	Common Stock	2,039	$13.76	$28,057
Purchase	10 Jun 2024	SABA CAPITAL MANAGEMENT, L.P. 10 percent owner 10 percent owner	Common Stock	9,704	$13.71	$133,042
Purchase	7 Jun 2024	SABA CAPITAL MANAGEMENT, L.P. 10 percent owner 10 percent owner	Common Stock	3,763	$13.72	$51,628
Purchase	6 Jun 2024	SABA CAPITAL MANAGEMENT, L.P. 10 percent owner 10 percent owner	Common Stock	9,598	$13.8	$132,452

HQL insider trading transactions

Tekla Life Sciences Investors
Latest News

Sunday, 24 November 2024
09:30	5 Best CEFs This Month For 8.5% Yield (November 2024)	seekingalpha.com
Sunday, 27 October 2024
09:00	5 Best CEFs This Month For 9.5% Yield (October 2024)	seekingalpha.com
Sunday, 29 September 2024
09:30	5 Best CEFs This Month For 9% Plus Yield (September 2024)	seekingalpha.com
Friday, 9 August 2024
16:17	abrdn U.S. Closed-End Funds Announce Distribution Payment Details	accesswire.com
Tuesday, 28 May 2024
03:24	Finding Opportunities In The Closed-End Fund World	seekingalpha.com
Thursday, 21 March 2024
07:59	abrdn Healthcare Investors (HQH), abrdn Life Sciences Investors (HQL), abrdn Healthcare Opportunities Fund (THQ), and abrdn World Healthcare Fund (THW) Announce Investment Team Update	accesswire.com
Wednesday, 10 January 2024
18:30	The Month In Closed-End Funds: December 2023	Seeking Alpha
Wednesday, 27 September 2023
14:34	HQL: Hold Your Investments In This Healthcare CEF For Strong, Steady Yield	Seeking Alpha
Thursday, 29 June 2023
08:06	HQL: 13% Discount Creates An Opportunity	Seeking Alpha
Wednesday, 8 March 2023
03:27	HQL: Boom-Bust Returns May Not Be Suitable For High Distribution Yield	Seeking Alpha
Monday, 9 January 2023
12:29	Equity CEFs: Top Picks For 2023	Seeking Alpha
Wednesday, 14 December 2022
09:30	5 Best CEFs To Buy This Month (December 2022)	Seeking Alpha
Thursday, 8 December 2022
10:36	Equity CEFs: What's Going On With Tekla's HQH And HQL?	Seeking Alpha
Sunday, 23 October 2022
08:39	Tekla Life Sciences Investors: 10% Yield And Trading 10.5% Below NAV	Seeking Alpha
Tuesday, 12 July 2022
16:47	HQL: A Biotechnology Equity CEF With No Leverage	Seeking Alpha
Wednesday, 27 April 2022
14:38	HQL: Buy For The Yield, If You Can Stomach The Depreciation	Seeking Alpha
Tuesday, 1 March 2022
18:10	How To Protect Your Wealth, Grab 7%+ Dividends, In This Pullback	Forbes
Friday, 11 February 2022
05:05	Tekla Life Sciences Investors: Buy For Steady, Quarterly Dividend	Seeking Alpha
Tuesday, 14 December 2021
16:27	5 Closed-End Funds Bought In November	Seeking Alpha
Wednesday, 22 September 2021
11:20	Tekla Life Sciences Investors Rides Biotechnology Wave, Offers Growth With Steady Income	Seeking Alpha
Tuesday, 17 August 2021
11:10	Tekla Life Sciences Investors Declares Distribution	Business Wire
Sunday, 15 August 2021
18:50	5 Dividend Funds Yielding Up To 27.2%	Forbes

Frequently Asked Questions (FAQ)

What's the price of Tekla Life Sciences Investors stock today?

One share of Tekla Life Sciences Investors stock can currently be purchased for approximately $13.99.
When is Tekla Life Sciences Investors's next earnings date?

Unfortunately, Tekla Life Sciences Investors's (HQL) next earnings date is currently unknown.
Does Tekla Life Sciences Investors pay dividends?

Yes, Tekla Life Sciences Investors pays dividends and its trailing 12-month yield is 13.78% with 0% payout ratio. The last Tekla Life Sciences Investors stock dividend of $0.42 was paid on 26 Sep 2025.
How much money does Tekla Life Sciences Investors make?

Tekla Life Sciences Investors has a market capitalization of 368.41M and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 268.5% to 86.69M US dollars.
What is Tekla Life Sciences Investors's stock symbol?

Tekla Life Sciences Investors is traded on the NYSE under the ticker symbol "HQL".
What is Tekla Life Sciences Investors's primary industry?

Company operates in the Financial Services sector and Asset Management industry.
How do i buy shares of Tekla Life Sciences Investors?

Shares of Tekla Life Sciences Investors can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
When Tekla Life Sciences Investors went public?

Tekla Life Sciences Investors is publicly traded company for more then 33 years since IPO on 1 May 1992.
What is Tekla Life Sciences Investors's official website?

The official website for Tekla Life Sciences Investors is teklacap.com.
Where are Tekla Life Sciences Investors's headquarters?

Tekla Life Sciences Investors is headquartered at 100 Federal Street, Boston, MA.
How can i contact Tekla Life Sciences Investors?

Tekla Life Sciences Investors's mailing address is 100 Federal Street, Boston, MA and company can be reached via phone at +61 77728500.

Tekla Life Sciences Investors

teklacap.com

Exchange:

NYSE

Full time employees:

Industry:

Asset Management

Sector:

Financial Services

Tekla Life Sciences Investors is a closed-ended equity mutual fund launched and managed by Tekla Capital Management LLC. The fund invests in public equity markets across the globe. It seeks to invest in stocks of companies operating in the life sciences sector, including the biotechnology, pharmaceutical, diagnostics, managed healthcare, medical equipment, hospitals, healthcare information technology and services, devices and supplies industries, and in agriculture and environmental management industries. The fund primarily invests in growth stocks of small cap companies. It employs fundamental analysis with a focus on factors such as market position for services or products, experience of business management, technological expertise, and the ability either to generate funds internally to finance growth or to secure outside sources of capital to create its portfolio. The fund benchmarks the performance of its portfolio against the NASDAQ Biotech Index and the S&P 500 Index. It was formerly known as H&Q Life Sciences Investors fund. Tekla Life Sciences Investors was formed on February 20, 1992 and is domiciled in the United States.

+61 77728500

100 Federal Street
Boston, MA 02110

CIK: 0000884121
ISIN: US87911K1007
CUSIP: 87911K100